Physician profile
Robert B Devney
NPI 1770668576
$4,389.49
in general payments reported to CMS, 2019-2025
28 companies · $946 in 2025
The $946 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $134 · 2021: $111 · 2022: $348 · 2023: $708 · 2024: $757 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $656.60 | 2019-2023 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $531.66 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $333.69 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $333.24 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $260.08 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $245.91 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $213.31 | 2019-2020 | |
| Corium, LLC | $201.24 | 2022-2024 | Azstarys |
| Lundbeck LLC | $181.05 | 2019-2024 | Rexulti |
| Alkermes, INC. | $175.76 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $155.98 | 2022-2025 | Invega Sustenna, Invega Trinza, Risperdal |
| Axsome Therapeutics, INC. | $138.03 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $130.91 | 2024-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $116.17 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $114.65 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $85.97 | 2023-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $76.21 | 2020-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $59.66 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $59.38 | 2019-2024 | |
| Sage Therapeutics, LLC | $50.09 | 2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $49.97 | 2019-2025 | |
| Shire North American Group INC | $48.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.27 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $37.47 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $29.98 | 2019 | |
| Vanda Pharmaceuticals INC. | $27.91 | 2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $20.76 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Devney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.